Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zopolrestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.84 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.84 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.84 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zopolrestat SCHEMBL15939751 | 0.92 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL49012 | 0.92 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 0.92 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL29353641 | 0.92 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129027 | 0.91 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15939601 | 0.90 | AKR1B1 (0.78) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7185596 | 0.89 | AKR1B1 (0.90) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15940171 | 0.86 | AKR1B1 (0.72) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7180777 | 0.85 | AKR1B1 (0.87) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7179887 | 0.85 | AKR1B1 (0.87) | AKR1B1AKR1B10AKR1A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263825-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | MYLARI BANAVARA L (US) | 2019-08-29 | — | — | US | disclosed |
| US-20170362237-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | MYLARI BANAVARA L (US) | 2017-12-21 | — | — | US | disclosed |
| US-20140228319-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | MYLARI BANAVARA L (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263825-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | AKR1C2, ALDOA, AKR1B1 | AKR1B1 3/4885AKR1B10 6/4885AKR1A1 5/4885 |
| US-20140228319-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | AKR1C2, ALDOA, AKR1B1 | AKR1B1 3/4885AKR1B10 6/4885AKR1A1 5/4885 |
| US-20170362237-A1 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | ALDOA, AKR1C2, AKR1B1 | AKR1B1 3/4885AKR1B10 7/4885AKR1A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.